UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) D ...

Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update August 5, 2021 Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and six months ended ...

Caladrius Biosciences, Inc. (CLBS) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer James Nisco – Vice President-Finance and Treasury Conference Call Participants Sara Nik – H.C. Wainwright Shubhendu Sen Roy – Brookline Pete Enderlin – MAZ Partners Operator Welcome to the Caladrius Biosciences Second Quarter 2021 Financial Results and Business Upda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) | Dela ...

Caladrius Biosciences, Inc. (CLBS) Q1 2021 Results Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants John Menditto - Vice President, Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer James Nisco - Vice President, Finance and Treasury Conference Call Participants Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences First Quarter 2021 Financial Results and Business Update Conference Call. [Operator Instructions] As a re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaw ...

caladrius Developing Regenerative Therapies that Reverse Chronic Disease David J. Mazzo, PhD President & Chief Executive Officer February 25, 2021 | Nasdaq: CLBS Forward-looking statement 2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this presentation, and involve certain risks and uncertainties. All statements other than state ...

Caladrius Biosciences, Inc. (CLBS) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants John Menditto - Vice President, Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer Conference Call Participants Emanuela Branchetti - H.C. Wainwright Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences Fourth Quarter and Year End 2020 Financial Results and Business Update Conference Call. [Operator Instructions] As a rem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ...

caladrius Developing Regenerative Therapies that Reverse Chronic Disease David J. Mazzo, PhD President & Chief Executive Officer January 19, 2021 | Nasdaq: CLBS Forward-looking statement 2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this presentation, and involve certain risks and uncertainties. All statements other than statem ...